Cardiac contractility modulation therapy promising for patients with HFpEF

A pilot study assessing cardiac contractility modulation (CCM) therapy in patients with heart failure and preserved ejection fraction (HFpEF) displayed a significant improvement in the health status of patients following this therapy. Further studies are warranted to establish the applicability of CCM in patients with HFpEF.

“CCM therapy has demonstrated to be efficacious in patients with HF and reduced or mid-range ejection fractions,” mentioned Prof. Cecilia Linde (Karolinska University Hospital, Sweden) [1]. The current prospective, multicentre CCM-HFpEF pilot study (NCT03240237) aimed to assess the efficacy and safety of CCM in patients with symptomatic HFpEF (n=47). The primary efficacy endpoint was the mean change in Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score through week 24, whereas the primary safety endpoint was the number of device-related and procedure-related complications.

After 24 weeks, CCM therapy was associated with a mean improvement of 18.0 points on the KCCQ overall summary score (P<0.001). Similarly, the mean change in KCCQ clinical summary score from baseline was 15.3 points (P<0.001). As for safety, 3 procedure-related complications were reported in 3 patients and no device-related complications were observed after 24 weeks, resulting in an event-free rate of 93.6%. In addition, only 2 patients experienced ≥1 HF hospitalisation during the study (168 days) compared with 15 patients in the year before CCM was administered.

In conclusion, CCM therapy may offer improvements in the health status of patients with symptomatic HFpEF. However, further studies are needed to establish the efficacy and safety of CCM therapy in the HFpEF population.

 

1. 
   
   1. Linde C, et al. CCMHFpEF: Is CCM Therapy safe and effective in patients with HFpEF? LBT Devices, Heart Failure 2022, 21–24 May, Madrid, Spain.

 

Copyright ©2021 Medicom Medical Publishers





Posted on 23 May, 202213 June, 2022